Clonal Heterogeneity in Urothelial Cancer
Bishoy Faltas, MD, clinical fellow, Weill Cornell Medical College, discusses clonal heterogeneity in platinum-resistant metastatic urothelial cancer.
Clinical Pearls
Bishoy Faltas, MD, clinical fellow, Weill Cornell Medical College, discussesclonal heterogeneity in platinum-resistant metastatic urothelial cancer.
- This study found a significant degree of both inter- and intra-patient heterogeneity.
- There were differences in the patterns of evolution of molecular alterations in these samples.
- Subclonal mutations went on to be enriched in and constitute most mutations in metastatic samples.
- Mutations in primary samples were identified that were not enriched in metastatic samples.
- It was found that the metastatic samples continued to change even after evolving from the primary tumor samples.
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
